Under the terms of the deal, ‌Lantheus' shareholders will get $102.50 per share in cash when the deal closes, along with the ...

Novartis paid out $195 million in 2020 to settle a criminal claim brought by the federal government – at the time, the ...

The last mega-mergers between big pharma companies were BMS' $74 billion deal with Celgene in 2019 and the $63 billion AbbVie ...

Supernus Pharma and Indivior have signed an all-stock merger agreement that would establish a new company, focused on central ...

Analysts said the ZEUS failure makes ziltivekimab a high-risk asset and increases the pressure on Novo Nordisk to carry out ...

A cannabis-derived drug developed by Germany's Vertanical has shown efficacy in phase 3 as a treatment for chronic pain, offering the prospect of an alternative to opioid drugs that carry the risk of ...

Agentic AI represents a bridge between predictive, generative, and autonomous systems. Building that bridge to last requires ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on ...

At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type I (LAD-I), a rare and life-threatening immune disorder that leaves patients ...

A US judge has ordered that Novo Nordisk must face some allegations in court that it defrauded investors by making misleading ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.